Cresco Labs Inc (OTCMKTS:CRLBF) has received an average rating of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.25.
A number of equities research analysts have issued reports on CRLBF shares. LADENBURG THALM/SH SH started coverage on shares of Cresco Labs in a report on Friday, February 21st. They set a “buy” rating for the company. Cantor Fitzgerald started coverage on shares of Cresco Labs in a report on Thursday, February 13th. They set an “overweight” rating and a $12.00 price objective for the company. Finally, Roth Capital started coverage on shares of Cresco Labs in a report on Friday, December 20th. They set a “buy” rating and a $12.00 price objective for the company.
CRLBF traded down $0.32 during trading on Friday, reaching $4.82. 712,351 shares of the company traded hands, compared to its average volume of 493,235. Cresco Labs has a 12-month low of $4.39 and a 12-month high of $14.39. The firm has a fifty day simple moving average of $5.82 and a 200 day simple moving average of $6.45.
About Cresco Labs
Cresco Labs Inc cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flower, vape pens, and various forms of extracts under the cresco and Reserve brands; precisely-dosed and non-combustible products, including tinctures, capsules, salves, sublingual oils, and transdermal patches under the Remedi brand; culinary-backed and cannabis-infused edibles under the Mindy's Artisanal brand; and fruity confections under the Mindy's Kitchen brand.
Featured Article: Debt-To-Equity Ratio
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.